Previous studies found that there was a negative correlation between TMB and clinical outcomes in metastatic EGFR-driven NSCLC patients, and patients with high TMB were more likely to achieve shorter TKI-PFS (16, 54). This evidence concerns the gene EGFR and non-small cell lung carcinoma.